NetraMark Holdings (TSE:AIAI) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NetraMark Holdings Inc., a leader in AI software for clinical trial analytics, has reported significant progress in Q3, including the full commercialization of its proprietary AI platform validated by a major pharmaceutical company. They’ve refined their market strategy to focus on CNS and Oncology sectors and have secured a substantial client with over $10B USD market cap, resulting in four contracts. NetraMark’s AI technology aims to mitigate the high failure rates of clinical trials in the pharmaceutical industry by improving decision-making and potentially saving millions in investment.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.